Are MNC funds a safe bet in the current scenario?
MNC Funds or mutual fund schemes that invest mostly in multinational companies are gaining currency these days. MNCs are always bankable, especially in the current bleak economic scenario due to the pandemic.
MNC arms yet to take a call on Facebook ads
Unilever’s India subsidiary, Hindustan Unilever, hasn’t taken a call on the matter yet. HUL has c...
Govt amends I-T rules for faster resolution of multinational corporations' tax disputes under MAP
The Central Board of Direct Taxes (CBDT) h...
Haryana to woo companies keen to move from China
The Government of Haryana has prepared a strategy to create windows in the existing state policies that would ensure quick setting up of manufacturing facilities in any industrial estate of the choice of investors wanting to shift base from China. Government is reaching out to these Companies to understand their individual requirements.
Pharma stocks would be market outperformers over the next 5-6 years: Dalal & Broacha
Indian pharma companies have two or three legs of business -- India, US and rest of world.
Banks in a spot post China logjam
Banks, which have issued letters of credit (LC) to finance Indian importers, have been told by leading courier companies that trade documents will not be delivered following delays in customs clearance in India, two senior bankers told ET.
Tells us how you conduct your business: NFRA asks top professional services firms
The regulator sent a form to the firms seeking details of their client roster, the fees they charge, salaries of partners, money made from non-audit assignments and the qualified opinions they had made during the audit of companies in financial duress.
Chinese sold electronics worth Rs 1.4 lakh crore in India in 2019
Chinese companies registered sales of nearly Rs 1.4 lakh crore in the Indian electronics market last year.
Out of Work: Layoffs and furloughs across sectors have rendered thousands helpless
Behind the staggering number of layoffs are individual stories of loss — of income, financial security, confidence and identity. To capture some of the turmoil and anxiety, ET Magazine spoke to employees who have been recently laid off across various sectors. While some have savings and a security net, others are in a precarious situation, with dependants and loans.
MNC royalties moderate under investor scrutiny
The study said that the payments by MNCs to parents are legitimate.
China cos’ India arms raise ECBs to scale FDI wall
Any investment from countries sharing a land border with India, including the China and Hong Kong region, will need special pre-approval, the government said last month. If a company needs emergency funding from China, the ECB is the best route since the transaction can be closed within a week, legal experts said.
Back-office realty with MNC tenants to be least hit by virus
Commercial real estate catering to back-office operations for multinationals is expected to be the least affected by the current economic crisis triggered by the coronavirus pandemic. This is because the tenants are financially strong multinationals, spending only a fraction of their expenses on rent even as they gain by the weakening rupee.
ED attaches JP Morgan assets worth Rs 187 crore, MNC in Supreme Court denies wrong doing in Amrapali case
The firm, JP Morgan India on other hand denied any wrong doing and said that attachment of properties by the Enforcement Directorate is blatantly illegal as it was not part of any kind of financial dealing with Amrapali Group and it was JP Morgan Singapore and Mauritius which had allegedly invested in the real estate group.
MNC tax: Delays plague mutual agreement process
MAP agreements are not made public, but a case that had hit the headlines was that of Nokia, where significant tax demands of above Rs. 2,000 crore were made on the Indian company.
Serum Institute, AstraZeneca in talks for vaccine Supply
AstraZeneca also received $1 billion from the US government’s Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in September. The development programme includes a Phase-III clinical trial with 30,000 participants and a paediatric trial. The vaccine is currently undergoing Phase-I and II trials.
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service